Given that GIP-mediated insulinotropic effects are diminished under chronic hyperglycemia [76, 77], the biased agonism of tirzepatide toward the GLP-1 receptor plays a crucial role in its efficacy. The gene discussed is GIP; the disease is Hyperglycemia.